ArticleMolecular therapy. Nucleic acids2026
Influenza B mosaic HA mRNA-LNP vaccines are cross-reactive and protective in mice.
Article in Molecular therapy. Nucleic acids, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Influenza B viruses cause about one-third of annual influenza infections, leading to significant respiratory illness. Vaccination remains the most effective strategy to mitigate the health and socio-economic burdens of influenza. Recent advances focus on developing a universal influenza B vaccine using chimeric hemagglutinin (HA) (cHA) and mosaic HA (mHA) constructs. cHA vaccines are engineered by replacing the entire head domain of influenza B HA with those from exotic avian influenza viruses, while mHA vaccines involve substituting only the immunodominant epitopes in the HA head domain. In this study, we assessed the immunogenicity of cHA and mHA vaccines delivered via the nucleoside-modified mRNA-lipid nanoparticle platform. Sequential immunization with these constructs in murine models stimulated immune responses targeting conserved HA epitopes, enhancing cross-protection against diverse influenza B virus strains. Notably, mHA vaccination induced higher levels of cross-reactive antibodies and antigen-specific CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.